H1 2016 Results

Thursday, 28 July 2016

Pascal Soriot, Chief Executive Officer, commenting on the results said:

“Our performance in the first half was in line with expectations, reflecting the anticipated near-term patent expiry challenges and the phasing of Externalisation Revenue in 2016. Our Growth Platforms continued to advance and made up over 60% of Total Revenue. Importantly, our transformed pipeline is advancing quickly and delivering a rich flow of differentiated medicines, boding well for our return to growth.

Alongside positive results for our first potential Respiratory biologic medicine, benralizumab, and for Tagrisso in second-line lung cancer, we are encouraged by the rapid patient recruitment in our Immuno-Oncology durva/treme combination programmes. This strong scientific momentum is set to continue, in particular where we anticipate key Immuno-Oncology data.”

Downloads

H1 2016 Results announcement (PDF 12mb)

H1 2016 Presentation (PDF 1.4mb)

H1 2016 Clinical trials appendix (PDF 2.2mb)

H1 2016 Results transcript (PDF 229)

tags

  • Corporate and financial